Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00133692 · ClinicalTrials.gov registry record · Phase 4
INVEST: INternational VErapamil SR Trandolapril STudy
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 22,000
- Enrollment target
NCT00133692 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 22,000 participants.
The verdict
NCT00133692, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22,000 participants
- Enrollment target
Study Summary
Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release \[SR\] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).
Interventions
- DRUG Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)
- DRUG Atenolol/HCTZ/Trandolapril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,000 participants |
| Start Date | 1997-09 |
| Est. Completion | 2003-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00133692
The ClinicalTrials.gov registry entry for NCT00133692 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ) is the first listed.
NCT00133692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00133692 about?
NCT00133692 is a clinical study titled "INVEST: INternational VErapamil SR Trandolapril STudy". Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this...
What is the current status of trial NCT00133692?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22,000 participants. The study started on 1997-09. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00133692?
The interventions under investigation include: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ) (DRUG), Atenolol/HCTZ/Trandolapril (DRUG).
Who is sponsoring clinical trial NCT00133692?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.